A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.
Increased tobacco exposure is linked with a higher risk of developing second primary lung cancers (SPLCs).
Researchers have found that there is a strong association between lung tissue with human papillomavirus (HPV) infection.
Patients with lung cancer that have developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival when continued use of the drug with chemotherapy is utilized.
A new drug, anamorelin, has been found to improve appetite and body mass in patients with advanced lung cancer who are experiencing cancer anorexia and cachexia.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|